查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654644

全球介入影像市場 - 2025 - 2033

Global Interventional Imaging Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 167 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球介入影像市場規模達到 92.1 億美元，預計到 2033 年將達到 166.4 億美元，2025-2033 年預測期內的複合年成長率為 6.8%。

介入影像是指利用先進的影像技術來引導和輔助微創手術或介入。它涉及即時成像技術，以便在醫療過程中可視化身體內部結構，使醫療專業人員能夠高精度、準確地執行程序。介入影像可以在手術過程中對目標區域（例如血管、器官或組織）進行連續、即時的可視化。這對於確保正確放置器械和最大限度地減少對周圍組織的傷害至關重要。

受人們對微創手術的偏好不斷增加、慢性病盛行率不斷上升以及技術進步日益加快的推動，介入影像市場正在經歷顯著成長。例如，2024 年 6 月，GE HealthCare 和 MediView XR Inc. 發布了 OmnifyXR 介入套件的第一個安裝。它將即時傳輸醫學影像的全像平視顯示器與3D（3D）解剖模型視覺化和強大的成像技術相結合。它能夠透過遠端合作，透過廣泛的干涉技術提供精準護理。

市場動態：

促進因素與約束因素

科技進步日新月異

不斷成長的技術進步極大地推動了介入影像市場的成長，並有望在預測期內透過提高微創手術的準確性、速度和安全性來推動市場的發展。人工智慧正在透過改善視覺化、影像分析、即時決策和預測模型來改變介入成像。人工智慧演算法可以從影像資料中快速識別腫瘤或阻塞等異常情況，幫助臨床醫生做出更快、更準確的決策。

例如，2024 年 12 月，荷蘭皇家飛利浦公司宣布，新推出的 CT 5300 系統透過人工智慧和智慧工作流程自動化功能增強了人們對臨床決策支援的信心。飛利浦 CT 5300 結合創新的硬體、軟體和人工智慧，為更多患者提供高品質的篩檢和介入成像，包括透過自動化人工智慧的飛利浦高級視覺化工作區應用程式提供閱讀支援。

此外，3D 和 4D 成像可提供身體結構的即時高解析度視圖，有助於介入期間的精確導航。這項技術對於指導血管成形術、活體組織切片和腫瘤消融等手術至關重要。 3D 和 4D 影像的採用預計將迅速增加，從而促進市場成長，尤其是在北美和歐洲等醫療保健基礎設施高度發展的地區。

例如，2024年8月，西門子醫療宣布，具有人工智慧（AI）特性的新型專用心血管超音波系統ACUSON Origin已獲得FDA批准。這些特質可以幫助醫生更有效地執行心臟手術，例如診斷、結構性心臟病和電生理學。新型 AcuNav Lumos 4D ICE（心內超音波心動圖）導管僅與 ACUSON Origin 相容，能夠改善困難心臟手術的影像效果。

嚴格的監管框架

嚴格的監管框架對介入影像市場的成長構成了重大挑戰，因為它會造成延誤、增加成本並限制採用新技術的速度。美國 FDA（食品藥物管理局）和歐洲藥品管理局（EMA）等監管機構對醫療器材（包括介入影像系統）實施了嚴格的核准流程。這些過程通常涉及大量臨床試驗、文件和審查，之後產品才能進入市場。

不同地區的醫療器材監管標準差異很大。這些差異使介入影像公司的全球市場策略變得複雜，因為它們必須遵守每個地區不同的核准流程和認證要求（例如美國的 FDA、歐洲的 CE 標誌和澳洲的 TGA）。

例如，由於安全性和功效標準的差異，FDA 批准的產品可能無法立即在歐盟或亞洲銷售。這需要額外的測試和認證，這可能會延遲進入市場並增加營運的複雜性。這些地區監管差異為試圖在全球擴張的公司製造了障礙，並減緩了不合規地區市場的成長，限制了他們獲得最新技術的管道。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類
  • 影像方式片段
  • 按應用程式截取的程式碼片段
  • 按過程類型分類的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 不斷進步的技術
    • 限制
      • 嚴格的監管框架
    • 機會
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • 新興創業公司和關鍵創新者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：介入性影像市場（依產品類型）

  • 介入性影像系統
    • MRI 系統
    • 超音波成像系統
    • CT 掃描儀
    • 血管攝影系統
    • 其他
  • 介入影像配件
    • X光偵測器
    • C 臂
    • 影像增強器
  • 軟體
  • 耗材
    • 導管
    • 導絲
    • 針
    • 其他

第 6 章：介入性影像市場（以影像方式分類）

  • X 光影像
  • 電腦斷層掃描 (CT)
  • 磁振造影（MRI）
  • 超音波成像
  • 其他

第 7 章：介入性影像市場（按應用）

  • 心臟病學
  • 腫瘤學
  • 神經病學
  • 泌尿科和腎臟科
  • 胃腸病學
  • 肌肉骨骼
  • 其他

第 8 章：介入性影像市場（依手術類型）

  • 診斷程序
  • 治療程序

第 9 章：介入性影像市場（依最終用戶分類）

  • 醫院
  • 專科診所
  • 診斷中心
  • 門診手術中心
  • 其他

第 10 章：介入性影像市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第 12 章：公司簡介

  • GE HealthCare
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 關鍵進展
    • SWOT 分析
  • Koninklijke Philips NV
  • Siemens Healthineers AG
  • CANON MEDICAL SYSTEMS USA, INC.
  • FUJIFILM Holdings Corporation
  • Lumibird Medical
  • Boston Scientific Corporation
  • Terumo Corporation
  • Guerbet
  • Shimadzu Corporation

第 13 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 14 章：附錄

簡介目錄
Product Code: MI9090

The global interventional imaging market reached US$ 9.21 billion in 2024 and is expected to reach US$ 16.64 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033.

Interventional imaging refers to the use of advanced imaging techniques to guide and assist minimally invasive procedures or interventions. It involves real-time imaging technology to visualize internal structures of the body during medical treatments, enabling healthcare professionals to perform procedures with high precision and accuracy. Interventional imaging provides continuous, real-time visualization of the target area, such as blood vessels, organs, or tissues, during a procedure. This is essential for ensuring the correct placement of instruments and minimizing damage to surrounding tissues.

The interventional imaging market is experiencing significant growth, driven by a rising preference for minimally invasive procedures, a rising prevalence of chronic diseases and increasing technological advancements. For instance, in June 2024, GE HealthCare and MediView XR Inc. released the first installation of the OmnifyXR interventional suite. It combines a holographic heads-up display that streams real-time medical images with three-dimensional (3D) anatomical model visualization and powerful imaging technology. It enables remote cooperation for the delivery of precision care across a wide range of intervention techniques.

Market Dynamics: Drivers & Restraints

Rising technological advancements

The rising technological advancements are significantly driving the growth of the interventional imaging market and are expected to drive the market over the forecast period by enhancing the accuracy, speed, and safety of minimally invasive procedures. Artificial intelligence is transforming interventional imaging by improving visualization, image analysis, real-time decision-making, and predictive modeling. AI algorithms can quickly identify abnormalities, such as tumors or blockages, from imaging data, helping clinicians make faster, more accurate decisions.

For instance, in December 2024, Royal Philips announced a boost in confidence in clinical decision support with AI and smart workflow automation capabilities in the recently introduced CT 5300 system. Philips CT 5300 combines innovative hardware, software and artificial intelligence for high-quality screening, and interventional imaging accessible to more patients, including reading support with Automated AI-enabled Philips Advanced Visualization Workspace applications.

Additionally, 3D and 4D imaging provide real-time, high-resolution views of the body's structures, aiding in precise navigation during interventions. This technology is crucial for guiding procedures like angioplasty, biopsy, and tumor ablation. The adoption of 3D and 4D imaging is expected to increase rapidly, contributing to market growth, especially in regions with high healthcare infrastructure, like North America and Europe.

For instance, in August 2024, Siemens Healthineers announced that ACUSON Origin, a new specialized cardiovascular ultrasound system with artificial intelligence (AI) characteristics, has received FDA clearance. These qualities can help physicians execute cardiac operations more effectively, such as diagnostics, structural heart disease, and electrophysiology. The new AcuNav Lumos 4D ICE (intracardiac echocardiography) catheter, which is only compatible with the ACUSON Origin, enables improved imaging for difficult heart surgeries.

Strict regulatory frameworks

Strict regulatory frameworks pose a significant challenge to the growth of the interventional imaging market by creating delays, adding costs and restricting the speed at which new technologies can be adopted. Regulatory bodies, such as the FDA (Food and Drug Administration) in the U.S. and the European Medicines Agency (EMA) in Europe, impose stringent approval processes for medical devices, including interventional imaging systems. These processes often involve extensive clinical trials, documentation, and reviews before products can be introduced to the market.

Regulatory standards for medical devices vary significantly across regions. These differences complicate the global market strategy for interventional imaging companies, as they must adhere to different approval processes and certification requirements in each region (e.g., FDA in the U.S., CE marking in Europe, and TGA in Australia).

For instance, a product approved by the FDA might not be immediately eligible for sale in the EU or Asia due to differences in safety and efficacy standards. This requires additional testing and certifications, which can delay market entry and increase operational complexity. These regional regulatory discrepancies create barriers for companies trying to expand globally and slow down the growth of the market in non-compliant regions, limiting access to the latest technologies.

Segment Analysis

The global interventional imaging market is segmented based on product type, imaging modality, application, procedure type, end-user and region.

Product Type:

The interventional imaging systems segment is expected to dominate the interventional imaging market share

Interventional imaging systems such as MRI systems, ultrasound imaging systems and angiography systems provide real-time, detailed visual guidance during minimally invasive procedures, such as angioplasty, biopsy and tumor ablation. These systems are integral to ensuring precise targeting, reducing complications, and improving patient outcomes.

For instance, in cardiology, systems like GE Healthcare's fluoroscopy systems are widely used to guide procedures such as coronary angioplasty and stent placement, ensuring correct catheter positioning in real time. The demand for such procedures, which benefit from precise guidance, is increasing, positioning interventional imaging systems as the market leader.

Advanced imaging technologies, such as 3D/4D imaging, robotic-assisted systems and AI-powered diagnostic tools, are transforming interventional imaging systems, enhancing their accuracy, efficiency, and applicability. For instance, the Siemens Healthineers' ARTIS pheno system integrates 3D imaging with cutting-edge advanced robotic-assisted interventions, for multiple surgical and interventional procedures. The continuous innovation in imaging systems, such as the integration of AI for faster and more accurate imaging analysis, ensures their dominance in the interventional imaging market.

Geographical Analysis

North America is expected to hold a significant position in the interventional imaging market share

North America, particularly the United States, is home to major medical imaging companies such as GE Healthcare, Philips, and Siemens Healthineers. These companies are at the forefront of developing and commercializing new imaging technologies, including 3D/4D imaging, robotic-assisted interventions, and AI-powered imaging systems.

For instance, in November 2024, Philips Healthcare launched a limited release of the LumiGuide system, a new light-based catheter guidance system for cath labs that represents a step toward radiation-free interventional imaging. The focus of the technology is endovascular aortic procedures. LumiGuide system works exclusively with compatible Philips interventional systems such as Azurion and is the second-generation solution to use FORS. These continuous technological advancements and innovations in the region solidify North America's position as a leader in the interventional imaging market.

There is a rising preference for minimally invasive procedures in North America due to the benefits of shorter recovery times, reduced risks, and lower healthcare costs. Interventional imaging systems are essential in guiding these procedures with precision, which further drives their demand. For instance, the growing use of angioplasty and stent placement procedures for coronary artery disease (CAD) is driving the demand for advanced fluoroscopy and angiography systems in the U.S. The increasing demand for minimally invasive procedures is fueling the growth of the interventional imaging market in North America, as these systems are crucial for performing such interventions with high accuracy.

Asia-Pacific is growing at the fastest pace in the interventional imaging market

Asia-Pacific is seeing an influx of technological advancements in interventional imaging, with an increasing number of local manufacturers producing cost-effective, high-quality imaging systems. This trend is driving adoption by making interventional imaging more accessible in emerging markets. The presence of leading manufacturers such as India's Medtronic and Philips India and more affordable imaging systems are driving the growth of the interventional imaging market in the region, making advanced technologies more accessible to a broader population.

For instance, in November 2024, Philips India launched the new Azurion to expert interventionalists in cardiology, neurology, vascular medicine, and surgery in India. The new interventional system is intended to speed up neurovascular operations and assist care teams in making the correct decisions faster, treating more patients, and achieving better results. It has increased C-arm rotation and angulation. It also includes parking facilities for quick transitions from 2D to 3D imaging, comprehensive table-side control that eliminates the need to leave the sterile field, automatic beam rotation to obtain correctly oriented images for all angulations and rotations, and a new head immobilizer to support improved stroke care.

Competitive Landscape

The major global players in the interventional imaging market include GE HealthCare, Koninklijke Philips N.V., Siemens Healthineers AG, CANON MEDICAL SYSTEMS USA, INC., FUJIFILM Holdings Corporation, Lumibird Medical, Boston Scientific Corporation, Terumo Corporation, Guerbet, Shimadzu Corporation and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global interventional imaging market report delivers a detailed analysis with 78 key tables, more than 80 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Imaging Modality
  • 2.5. Snippet by Application
  • 2.6. Snippet by Procedure Type
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Strict Regulatory Frameworks
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Interventional Imaging Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Interventional Imaging Systems*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. MRI Systems
    • 5.2.4. Ultrasound Imaging Systems
    • 5.2.5. CT Scanners
    • 5.2.6. Angiography Systems
    • 5.2.7. Others
  • 5.3. Interventional Imaging Accessories
    • 5.3.1. X-ray Detectors
    • 5.3.2. C-arms
    • 5.3.3. Image Intensifiers
  • 5.4. Software
  • 5.5. Consumables
    • 5.5.1. Catheters
    • 5.5.2. Guidewires
    • 5.5.3. Needles
    • 5.5.4. Others

6. Interventional Imaging Market, By Imaging Modality

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 6.1.2. Market Attractiveness Index, By Imaging Modality
  • 6.2. X-Ray Imaging*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Computed Tomography (CT)
  • 6.4. Magnetic Resonance Imaging (MRI)
  • 6.5. Ultrasound Imaging
  • 6.6. Others

7. Interventional Imaging Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Cardiology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Oncology
  • 7.4. Neurology
  • 7.5. Urology and Nephrology
  • 7.6. Gastroenterology
  • 7.7. Musculoskeletal
  • 7.8. Others

8. Interventional Imaging Market, By Procedure Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 8.1.2. Market Attractiveness Index, By Procedure Type
  • 8.2. Diagnostic Procedure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Therapeutic Procedure

9. Interventional Imaging Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Diagnostic Centers
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. Interventional Imaging Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. GE HealthCare*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. Koninklijke Philips N.V.
  • 12.3. Siemens Healthineers AG
  • 12.4. CANON MEDICAL SYSTEMS USA, INC.
  • 12.5. FUJIFILM Holdings Corporation
  • 12.6. Lumibird Medical
  • 12.7. Boston Scientific Corporation
  • 12.8. Terumo Corporation
  • 12.9. Guerbet
  • 12.10. Shimadzu Corporation

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us